Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers-Reference-Cited by-同舟云学术

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

Published:2012-03-02 Issue:2 Volume:15 Page:275-286
ISSN:0969-6970
Container-title:Angiogenesis
language:en
Short-container-title:Angiogenesis

Author:

Allegrini Giacomo,Di Desidero Teresa,Barletta Maria Teresa,Fioravanti Anna,Orlandi Paola,Canu Bastianina,Chericoni Silvio,Loupakis Fotios,Di Paolo Antonello,Masi Gianluca,Fontana Andrea,Lucchesi Sara,Arrighi Giada,Giusiani Mario,Ciarlo Andrea,Brandi Giovanni,Danesi Romano,Kerbel Robert S.,Falcone Alfredo,Bocci Guido

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Biochemistry,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10456-012-9260-6.pdf

Reference53 articles.

1. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436

2. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16(8):1243–1252

3. Fioravanti A, Canu B, Ali G, Orlandi P, Allegrini G, Di Desidero T, Emmenegger U, Fontanini G, Danesi R, Del Tacca M, Falcone A, Bocci G (2009) Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol 619(1–3):8–14

4. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1 protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845–6848

5. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci 106(7):2353–2358

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombospondin-1 in drug activity and tumor response to therapies;Seminars in Cell & Developmental Biology;2024-03

2. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization;PLOS Computational Biology;2023-06-08

3. Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature;Journal of Clinical Medicine;2022-05-18

4. Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer;PeerJ;2022-04-19

5. Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment;Cancers;2021-10-28